Mupirocin calcium
Modify Date: 2024-01-03 17:25:33
Mupirocin calcium structure
|
Common Name | Mupirocin calcium | ||
|---|---|---|---|---|
| CAS Number | 104486-81-9 | Molecular Weight | 1039.32 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C52H86CaO18 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Mupirocin calciumMupirocin (BRL-4910A, Pseudomonic acid) calcium is an orally active antibiotic isolated from Pseudomonas fluorescens. Mupirocin calcium apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis[1][2]. |
| Name | Mupirocin calcium |
|---|
| Description | Mupirocin (BRL-4910A, Pseudomonic acid) calcium is an orally active antibiotic isolated from Pseudomonas fluorescens. Mupirocin calcium apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Mupirocin (BRL-4910A, Pseudomonic acid) calcium (0-100 μM; 48 h) shows antibacterial effect against staphylococci, streptococci and certain gram-negative bacteria, with MIC values range from 0.06-0.25 μg/mL (MIC50 =0.12 μg/mL, MIC90 =0.25 μg/mL)[1]. Mupirocin calcium is highly bound (95% bound) to human serum protein, thus results in activity inhibition in the presence of human serum[1]. Mupirocin calcium apparently exerts its antimicrobial activity by reversibly inhibiting isoleucyl-transfer RNA, thereby inhibiting bacterial protein and RNA synthesis[2]. Mupirocin calcium (2% ointment) reduces pro-inflammatory cytokines IL-1β and IL-17 level, decreases tumor necrosis factor-alpha (TNF-α) expression, and increases the leavel of vascular endothelial growth factor (VEGF)[4]. Mupirocin calcium inhibits MS (S. epidermidis ATCC 12228), MR (S. epidermidis (Se56-99)), and VIR (S. epidermidis (Se43-98)) with MICs of 0.25, 1.26, 1.59 mg/L[5]. Note: MIC, the minimum inhibition concentration. Cell Viability Assay[1] Cell Line: Staphylococcus aureus Concentration: 0-100 μM/mL Incubation Time: 24, 48 hours Result: Resulted in a 90 to 99% reduction at 24 h, with MIC values ranged from 0.12-1.0 μM/mL and MBC values ranged from 4.0-32 μM/mL at 48 h. |
| In Vivo | MRSA: Meticillin-resistant Staphylococcus aureus Mupirocin (BRL-4910A, Pseudomonic acid) calcium is well absorbed after oral and parenteral administration but serum antibiotic concentrations were short-lived as a result of extensive degradation to the antibacterially inactive metabolite, monic acid A[1]. Mupirocin calcium (2% ointment; external administration; twice daily; 3-6 d) decreases the total bacterial loads in the skin lesions with either topical treatment[3]. Mupirocin calcium (2% ointment; external administration; 4 d) alleviates MRSA-infected pressure ulcers in mice[4]. Mupirocin calcium (100 mg/mL; s.c.; 7 d) exerts prevention efficacy against vascular prosthetic graft infection due to Staphylococcus epidermidis[5]. Animal Model: MRSA skin infection model in mice (10-12 weeks old)[3] Dosage: 2% ointment Administration: External administration; twice daily; 3-6 days Result: Reduced the total bacterial loads in the skin lesions, and decreased by 2.0, 5.1 log10 CFU on day 3 and 6, respectively. Animal Model: Diabetic pressure ulcer mouse model (33.2-39.2 g)[4] Dosage: 2% ointment Administration: External administration; 4 days Result: Resulted less superficial mats of bacterial colonies, and improved histopathology evaluation. Animal Model: Adult male Wistar rats (weight 275-325 g)[5] Dosage: Impregnated with 100 μg of mupirocin/mL; segments:1.5 cm *1 cm2 Administration: Subcutaneous implantation; 7 days Result: Resulted in preventing S. epidermidis infection of the graft in a rat model with spontaneously bound to collagen-sealed Dacron grafts. |
| References |
| Molecular Formula | C52H86CaO18 |
|---|---|
| Molecular Weight | 1039.32 |
| Exact Mass | 1038.544 |